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Editor’s key points
† Diabetes mellitus and other
disorders of blood glucose
regulation are common in
perioperative patients.
† The optimal management of
perioperative dysglycaemia has
been shown to improve
perioperative outcomes.
† Guidelines and
recommendations aid in the
diagnosis and management of
perioperative abnormalities in
glucose homeostasis.
Summary. Theprevalenceof type2diabetesmellitus and thepotential for perioperative
dysglycaemia (hyperglycaemia, hypoglycaemia, stress-induced hyperglycaemia, or
glucose variability) continue to increase dramatically. The majority of investigations
on perioperative glycaemic control focused on critically ill patients and concentrated
on goals of therapy, level of intensity of insulin infusion, feeding regimes, concerns
over hypoglycaemia, and promulgation of recent guidelines calling for less strict
glucose control. Areas of perioperative glycaemic control that deserve further
investigation include preoperative identification of patients with undiagnosed type 2
diabetes and other forms of dysglycaemia, determination of appropriate
intraoperative glucose goals, and establishment of the impact and natural history of
perioperative abnormalities in glucose homeostasis. In the heterogeneous adult
perioperative population, it is unlikely that one standard of perioperative glycaemic
control is appropriate for all patients. This review presents recent evidence and expert
guidance to aid preoperative assessment, intraoperative management, and
postoperative care of the dysglycaemic adult patient.
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Theprevalenceof type2diabetesmellitus (DM)andperioperative
dysglycaemia [hyperglycaemia, hypoglycaemia, stress-induced
hyperglycaemia (SIH), or glucose variability (GV)] continue to in-
crease dramatically. The most recent US Centers for Disease
Control and Prevention National Health and Nutrition Examin-
ation Survey reports that the incidence of DM has tripled over
the past decade and projections are that it may triple again
within the next several decades. DM affects an estimated 25.8
million Americans (8.3%of theUS population). The vastmajority
of these individuals (.90–95%) have type 2 DM, but roughly
one-third of them remain undiagnosed (http://www.cdc.gov/
diabetes/pubs/pdf/ndfs_2011.pdf; http://www.cdc.gov/media/
pressrel/2010/r101022.html). The World Health Organization
(WHO) estimates the prevalence of DM at 60 million Europeans
(10.3% of men and 9.3% of women over the age of 25) (http://
euro.who.int/en/what-we-do/health-topics/noncommunicable-
diseases/diabetes/data-and-statistics).
The majority of investigations on perioperative glycaemic
control have focused on postoperative and intensive care unit
(ICU) patients. This work has concentrated on goals of
therapy, level of intensity of insulin infusion, feeding regimes,
concerns over hypoglycaemia, and promulgation of recent
guidelines calling for less strict glucose control. Areas
germane to perioperative glycaemic control that deserve
further investigation include: preoperative identification of
patients with undiagnosed type 2 DM and other forms of dys-
glycaemia, determination of appropriate intraoperative
glucose goals, and establishment of the impact and natural
history of perioperative abnormalities in glucose homeostasis.
The optimal management of the patient with perioperative
dysglycaemia continues to be debated. Hyperglycaemia,
hypoglycaemia, and GV are common features in critically ill
patients.1–5 Furthermore, SIH entails higher risks and often
poorer outcomes in hospitalized patients when compared
with equally dysglycaemic patients with known DM-induced
hyperglycaemia.4 5 Routine application of tight glycaemic
control, however, was called into question after the results
of various single-centre, ‘real-world’ studies and the multi-
centre, multinational NICE-SUGAR trial all reported either no
benefit with normalization of glucose during critical illness or
an increased incidence of hypoglycaemia and mortality.
Whether there is a true cause and effect association between
hypoglycaemia and outcome in the critically ill remains
unknown.6 7
Hospitals and institutions are encouraged tocreate theirown
policies, including in-house guidelines for DM management,
which cover the spectrum of all treated patient groups, ambu-
latory to critically ill.3 The creation of an institution-specific
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multidisciplinary team consisting of nursing, case managers,
and physician representatives to enhance unit or ward accept-
ance is suggested. The WHO surgical safety checklist bundle
should be established with a target blood glucose (BG) of
6–10 mM (108–180 mg dl21) (acceptable range 4–12 mM,
72–216 mg dl21).8
Perioperative dysregulation of glucose homeostasis can
result in elevated, lowered, or highly variable glucose levels.
Pancreatic b cell deficiency or dysfunction, peripheral insulin
resistance, inhibition of insulin release, counter-regulatory
hormonemodulation, or even glucose transporter deficiencies
can cause these physiological perturbations. Extensive discus-
sions about the pathophysiology of glucose regulation and DM
and also management of dysglycaemia in specific periopera-
tive patient populations (i.e. peripartum, cardiac, neurosurgi-
cal) are beyond the scope of this article and are well reviewed
elsewhere.9–14
This review focuses on preoperative identification, assess-
ment, and preparation of patients with known or previously
unrecognized abnormalities in glucose homeostasis; intrao-
perative management of glucose abnormalities; and ward,
intermediate care unit (IMCU), and ICUgoals for postoperative
and post-hospital discharge glucose management.
Preoperative
Preoperative identification of patients with DM, or those at risk
for perioperative dysglycaemia, provides a potential opportun-
ity to reduce morbidity and mortality. Early identification
facilitates timely intervention and allows arrangement of ap-
propriate perioperative and long-term follow-up. Anaesthe-
siologists, as leaders of the ‘surgical home’ model, are
perfectly poised to assist in this process.15 Anaesthesia care
providers should embrace the opportunity to assess, diagnose,
andultimately referpatients forcontinuedcare. Patienteduca-
tion, initiation of lifestyle changes, and implementation of
therapy have been shown to favourably impact microvascular
and macrovascular disease.16 Despite this, no current guide-
lines recommend preoperative DM screening in patients
without a documented history of hyperglycaemia.17
Diagnosis
Patients with DM have increased perioperative morbidity and
mortality.3 18–23 One must remember, however, that DM is
often found in combination with other significant risk factors
(sedentary lifestyle, smoking, obesity). These risk factors can
cloud the understanding of the specific role DM plays in peri-
operative morbidity and mortality. Nonetheless, diabetic
patients are at increased risk for postoperative infection, ar-
rhythmia, acute renal failure, ileus,12 stroke, myocardial is-
chaemia, increased length of hospital stay, and death.24 25
Many of these risks are present in prediabetic patients as
well.26 27 The American Diabetes Association (ADA) suggests
screening for DM in all adults at age 45 yr and earlier in those
with a BMI ≥25 kg m22 and one or more identified risk
factors (Table 1),28 and recommends placing individuals into
one of three categories: normal, increased risk (prediabetic),
anddiabetic basedupon fastingplasmaglucose (FPG), haemo-
globin A1C (HA1C), and 2 h oral glucose tolerance test (2-H
OGTT) results (Tables 2 and 3).29 These guidelines are broader
than the US Preventive Health Taskforce recommendations,30
which are undergoing revision and have been shown to under-
estimate significantly the prevalence of hyperglycaemia
(http://uspreventiveservicestaskforce.org/uspstopics.htm).
Undiagnosed DM
Notall patientswithDMareawareof their status.A2010Cleve-
land Clinic study found the rate of undiagnosed DM in 39 434
non-cardiac surgery patients was 10% and impaired fasting
glucose (IFG) 11%.31 Sheehy and colleagues15 showed that
24% of insured, elective surgery patients with recent primary
care visits had either undiagnosed DM or IFG discovered the
Table 1 Criteria for testing for DM in asymptomatic adult
individuals. *At-risk BMI may be lower in some ethnic groups; HDL,
high density lipoprotein; HA1C, haemoglobin A1C; IGT, impaired
glucose tolerance; IFG, impaired fasting glucose. Modified and
reprinted with permission from the American Diabetes
Association29
(1) Testing should be considered in all adults who are overweight
(BMI≥ 25 kg m22) and have additional risk factors:
† Physical inactivity
† First-degree relative with diabetes mellitus
† High-risk race/ethnicity (e.g. African American, Latino, Native
American, Asian American, Pacific Islander)
† Women who delivered a baby weighing .4.08 kg or were
diagnosed with gestational diabetes mellitus
† Hypertension (≥140/90mmHgorontherapy forhypertension)
† HDL cholesterol level ,0.90 mM (35 mg dl21), a triglyceride
level .2.8 mM (250 mg dl21), or both
† Women with polycystic ovary syndrome
† HA1C ≥5.7%, IGT, of IFG on previous testing
† Otherclinical conditionassociatedwith insulin resistance (e.g.
severe obesity, acanthosis nigricans)
† History of cardiovascular disease
(2) In the absence of above criteria, testing for diabetes mellitus
should begin at age 45 yr
(3) If results are normal, testing should be repeated at least at 3 yr
intervals, with consideration of more frequent testing
depending upon the initial results (e.g. those with prediabetes
should be tested yearly) and risk status
Table 2 Categories of increased risk for DM (prediabetes). For all
three tests, the risk is continuous, extending below the lower limit
of the range and becoming disproportionately greater at higher
ends of the range. FPG, fasting plasma glucose; 2-H OGTT, 2 h oral
glucose tolerance test; HA1C, haemoglobinA1C. Normal individuals
are defined as having an FPG ≤5.5 mM (100 mg dl21) (no caloric
intake for .8 h). Modified and reprinted with permission from the
American Diabetes Association29
1. FPG 5.6–6.9 mM (100–125 mg dl21) or,
2. 2-H OGTT 7.0–11.0 mM (140–199 mg dl21) or,
3. HA1C 5.7–6.4%
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day of surgery. Lauruschkat and colleagues32 found the inci-
dence of undiagnosed DM in 7310 German patients under-
going coronary artery bypass grafting (CABG) to be 5.2%
(known DM 29.6%). Interestingly, patients with undiagnosed
DM were more likely to require resuscitation, re-intubation,
and longer postoperative ventilation, and had higher peri-
operative mortality than both those without DM and those
with knownDM.32 This finding, alongwith those of other inves-
tigators, suggests that undiagnosed DM is an even greater risk
factor for perioperative morbidity and mortality than known
DM.33 This increased risk may be related to various factors,
including poor preventive care and less aggressive therapy by
the hospital-based team.
The role of HA1C
HA1C provides insight into glucose control over the preceding
3–4 months. Elevated preoperative HA1C is associated with
increased perioperative risk and holds promise as a preopera-
tive screening modality.34 35 Gustafsson and colleagues,35 in
a prospective study of 120 patients without known DM having
major colorectal surgery, were able to show patients with
preoperative HA1C . 6% were at significantly greater risk for
pneumonia, urinary tract infection, pleural effusions, andpost-
operative ileus, and had significantly elevated postoperative
glucose levels in this group of patients. Others retrospectively
linked preoperative HA1C to postoperative complications.
Dronge and colleagues36 showed that preoperative HA1C,7%
is significantly associated with decreased infectious complica-
tions includingpneumonia,wound infection, urinary tract infec-
tion, and sepsis. Hudson and colleagues37 demonstrated a
preoperativeHA1C. 6%innon-diabetics is independentlyasso-
ciatedwithgreaterearlymortalityafterelective cardiac surgery.
ElevatedHA1C, as amarkerof poor glycaemic control, corre-
lateswith increased perioperative risk in diabetic patients. Han
and Kang38 demonstrated a significant increase in wound
complications after total knee arthroplasty in diabetic patients
with HA1C .8%. Diabetic patients with an HA1C .6.5% have
an increased risk of pneumonia, urinary tract infection, and
superficial wound infections after elective cardiac surgery
when compared with diabetics with HA1C ,6.5%.
34 Currently,
the ADA suggests that practitioners consider obtaining an
HA1C on diabetic patients admitted to the hospital if the
result of testing in the previous 2–3 months is not available.
The ADA also suggests HA1C testing in patients with risk
factors for undiagnosed DM who exhibit hyperglycaemia in
the hospital.29
Although elevated HA1C is associated with adverse
outcomes, there is a lack of data to show delaying elective
surgery to correct HA1C is beneficial. Nonetheless, HA1C
screening does allow identification of unrecognized DM and
stratification of perioperative risk. Aggressive approaches to
lowering HA1C in non-surgical patients have not been shown
to decrease mortality.39 Future investigations will likely clarify
the role of preoperative HA1C management on modifying sur-
gical outcome.
Clinicians shouldbe reminded that theaccuracyofHA1Ccan
vary by measurement technique. Erroneous results are pos-
sible in patients with haemoglobinopathies, chronic bleeding,
iron deficiency, renal failure-induced anaemia, recent transfu-
sions, or ongoing haemolysis.40
Hyperglycaemia
Preoperative hyperglycaemia, independent of diabetic status,
increases the risk of perioperative morbidity and mortality.9
In a retrospective review of patients who developed peripros-
thetic joint infection after elective primary total hip or total
knee arthroplasty, preoperative BG was significantly elevated
compared with control patients.41 Preoperative BG .11.1 mM
(200mgdl21) is associatedwithdeep sternalwound infections
in patients undergoing CABG,42 and preadmission hypergly-
caemia is an independent risk factor for in-hospital symptom-
atic pulmonary embolism after major orthopaedic surgery.43
Hyperglycaemia before carotid endarterectomy is associated
with increased risk of perioperative stroke, transient ischaemic
attack, myocardial infarction, and death.44
The incidence of preoperative hyperglycaemia is striking. In
a prospective study of 493 non-diabetic patients undergoing
elective, non-cardiac surgery, 25% of patients had elevated
FPG the morning of surgery.45 Interestingly, known diabetic
status has been shown to provide some protection from the
adverse effects of hyperglycaemia.5 46 47 For patients on
general hospital wards without a history of DM, admission
hyperglycaemia increases mortality, length of stay (LOS), and
likelihood of discharge to a transitional care unit when com-
paredwith knowndiabetics.5Whether this increase inmorbid-
ity and mortality is related to undertreatment of elevated
glucose or other variables remains unknown.
Preoperative hyperglycaemia might not be related to DM,
but instead may be a response to acute illness or injury. This
‘SIH’ is defined as elevated BG that reverts to normal after
illness subsides and counter-regulatory hormone and inflam-
matory mediator surge abates.48 49 While physiologic, SIH
appears to independently increase the risk of perioperative
and critical illness morbidity and mortality.48 50–52 Kerby and
colleagues52 evaluated 6852 consecutive trauma patients for
the presence of SIH. These patients had an admission
glucoseof≥11.1mM(200mgdl21), HA1C, 6.5% (not diabetic
by HA1C criteria), and no past medical history of DM. When
matchedwith acontrol groupof similarage, sex, injury severity
Table 3 Criteria for the diagnosis of DM. HA1C, haemoglobin A1C;
FPG, fasting plasma glucose; 2-H OGTT, 2 h oral glucose tolerance
test. Modified and reprinted with permission from the American
Diabetes Association29
1. HA1C ≥6.5% or,
2. FPG ≥7.0 mM (126 mg dl21) or,
3. 2-H OGTT ≥11.1 mM (200 mg dl21) or,
4. In a patient with classic symptoms of hyperglycaemia or
hyperglycaemic crisis, a random plasma glucose ≥11.1 mM
(200 mg dl21)
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score, and revised trauma score, the SIH patients had a more
than two-fold increase in mortality. Surprisingly, admission
hyperglycaemia in diabetic patients did not significantly in-
creasemortality.52 In a retrospective study of 110 consecutive
orthopaedic trauma patients, Karunakar and Staples53 found
that a mean perioperative BG .12.2 mM (220 mg dl21) was
associated with seven-fold higher risk of infection in patients
with no known history of DM compared withmatched diabetic
patients. These data suggest that SIH can be a marker for se-
verity of illness and degree of counter-regulatory hormone
surge. One could also infer that previously diagnosed DM is in
some way protective, as opposed to new-onset SIH (with no
history of DM), although further investigations designed to
answer this question are needed.
Glucose variability
GV, defined as the degree of glucose level excursion over time,
is increasingly linked to poor ICU and perioperative outcomes.
In2006,Egiandcolleagues54 retrospectively lookedatboth the
mean glucose and standard deviation (SD) of BG, as amarker of
GV, in7049ICUpatients. Theauthors foundthatboth themean
and SD of BGwere significantly associatedwith ICUmortality.54
Subsequently, in 2008, Krinsley showed that the SD of BG level
was a predictor of mortality even within different ranges of
meanglucose. TheyalsodemonstratedGV tobeastrongerpre-
dictor of mortality than mean glucose.55 Further defining the
effects of GV in an ICU population, Hermanides and collea-
gues56 were able to show that the combination of high GV
and high mean glucose values was associated with the
highest overall ICU mortality. Interestingly, low GV was pro-
tective even in patients with high mean glucose levels. Their
findings suggest that high mean glucose is less harmful
when GV is low, and patients with identical mean glucose
can have different mortality rates depending on their GV.56 A
clear cause-and-effect relationship, rather than just a simple
association between GV and morbidity and mortality, has not
been clearly established. Further investigations are needed to
better delineate the importance of GV in the perioperative
period.
Preoperative evaluation and management
Patients at risk for perioperative dysglycaemia, whether they
arediabetic, prediabetic, or have SIH, deserve special consider-
ation before operation. Currently, there are limited data to
suggest that significant preoperative interventions aimed at
controlling dysglycaemia have an impact on outcome. The
aforementioned evidence seems to infer, however, that early
identification of these patients, if doing nothing more than
identifying them as ‘at risk’ and subsequently increasing pro-
vider vigilance, could have a significant impact on outcome.
Anaesthesia providers are perfectly poised to initiate this
process. Future investigations will further delineate the role
of early identification and any potential benefits of early
treatment.
Patients with a known history of DM should be thoroughly
evaluated before entering the operating suite. One should
have a detailed understanding of the history of the patient’s
disease, including: specific diagnosis (type 1 DM, type 2 DM,
gestational diabetes, etc.), duration of illness, current treat-
ment modalities, adequacy of control, and the presence and
severityof co-morbidities. This discussionwill focusonpatients
with a diagnosis of type 2 DM. It should be remembered,
however, that type 1DMpatients have anobligate physiologic-
al need for exogenous insulin (as they are unable to produce
theirown), havenormal insulin sensitivity, andcanhavesignifi-
cant comorbidities.57
Tables 4–6 provide a brief overview of the pharmacology of
common oral antidiabetic agents, non-insulin injectables, and
insulins. The preoperative management of diabetic medica-
tions should be tailored to the individual patient. Most
authors suggest holding oral antidiabetic agents and non-
insulin injectable medications on the day of surgery and not
before.58 At least one set of guidelines suggests holding met-
formin for 24–48 h before operation in patientswith renal dys-
function and in those who might receive i.v. contrast to
decrease the risk of perioperative lactic acidosis.58 Manage-
mentofpreoperative insulin therapyshould focuson theavoid-
ance of hypoglycaemia while maintaining reasonable BG
control. Patients at risk for hypoglycaemia before operation
include thosewith very strict glycaemic control, thosewith sig-
nificant daily GV, thosewith complicated insulin regimens, and
those who are taking insulin in combination with oral antidia-
betic agents.59 60 The majority of patients who receive insulin
are using a basal/bolus insulin schedule.29 61 Long-acting
agents are intended to supply a steady, basal supply of
insulin while shorter-acting agents (often referred to as
bolus, correctional or nutritional insulin) are used to counter
acute (post-prandial) increases in BG. Table 7 outlines a
general approach to the preoperative management of
insulin. This approach recommendsmodest alteration in long-
acting insulinandeliminationof short-acting insulinontheday
of surgery.58
Preoperative laboratory investigations in known diabetics
should include HA1C if not drawn in the previous 2–3
months,29 preoperative BG, and any additional testing needed
to further delineate the existence or severity of common co-
morbidities(i.e.nephropathy,cardiomyopathy).TheADArecom-
mends outpatient DM management to achieve an HA1C , 7%
(normal 4–7%).29 Although current guidelines do not support
liberal preoperative HA1C or BG screening, it may be wise to
expand such screening in certain patient populations (i.e.
cardiac, neurological, orthopaedic, transplant, and trauma
surgery).62 This would aid providers in identifying patients with
previously undiagnosed dysglycaemia, clarify glucose control
over the previous 3 months, and potentially increase provider
vigilance during the perioperative period.
Intraoperative
Hyperglycaemia
There are little data looking specifically at intraoperative BG
managementand itseffectsonpostoperativeoutcomes. Exist-
ing data are heavily skewed towards the cardiac surgical
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Table 4 Pharmacology of oral antidiabetic agents. Modified with permission from SAMBA58
Drug class: generic
(trade name)
Mechanism of action Half-life (h) Adverse effects
Biguanides Decrease hepatic gluconeogenesis, increase insulin
sensitivity
6–18 Diarrhoea, nausea, vomiting, lactic acidosis
Metformin (Glucophage) 24
Metformin extended
release
Sulphonylureas Stimulate insulin secretion, decrease insulin resistance 2–10 Hypoglycaemia, lactic acidosis
Chlorpropamide
(Diabenese)
Tolbutamide (Orinase)
Glimepride (Amaryl)
Glipizide (Glucotrol)
Glyburide (Diabeta,
Micronase)
Meglitinides Stimulate pancreatic insulin secretion 1 Hypoglycaemia
Repaglinide (Prandin)
Nateglinide (Starlix)
Thiazolidindiones Regulate carbohydrate and lipid metabolism, reduce
insulin resistance and hepatic glucose production
3–8 Fluid retention, increased cardiac risk
including congestive heart failure,
hepatotoxicity
Rosiglitazone (Avandia)
Pioglitazone (Actos)
a-Glucosidase inhibitors Reduce the intestinal absorption of ingested glucose 2–4 Gastrointestinal irritation, flatus
Acarbose (Precose)
Miglitol (Glyset)
Dipeptidyl peptidase-4
(DDP-4) inhibitors
Reduces breakdown of hormone-incretins (glucagon-like
peptide type-1), enhance insulin secretion, decrease
glucagon
Sitagliptin (Januvia)
Saxagliptin (Onglyza)
Table 5 Non-insulin injectables. Modified with permission from SAMBA58
Drug class: generic
(trade name)
Mechanism of action Half-life (h) Adverse effects
Exenatide (Byetta) Synthetic form of exendin 4, which has actions
similar to glucagon-like peptide type-1
6–10 Nausea, vomiting, weight loss, hypoglycaemia
when combined with sulphonylureas
Suppresses glucagon secretion and hepatic glucose
production
Suppresses appetite
Delays gastric emptying
Exenatide extended-release
(Bydureon)
Weekly dosing, see exenatide Days Medullary thyroid cancer, acute pancreatitis
Pramlintide (Symlin) Synthetic form of amylin, a naturally occurring
peptide that is cosecreted with insulin by b cells
2–4 Nausea, vomiting, weight loss, hypoglycaemia
with insulin
Suppresses post-prandial glucagon secretion and
hepatic glucose production
Enhances the effects of insulin
Suppresses appetite
Delays gastric emptying
Liraglutide (Victoza) Long-acting glucagon-like peptide type-1 agonist 11–15 Medullary thyroid cancer
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population.63–66 In 2007, Gandhi and colleagues67 reported a
retrospective investigation of 409 consecutive patients under-
going cardiac surgery at the Mayo Clinic. Patients who experi-
enced one of the primary endpoints (death, infectious,
cardiac, neurological, renal, or pulmonary) had significantly
higher initial, mean, and maximal intraoperative BG values.
Logistic regression analysis indicated that a 1.1 mM (20 mg
dl21) increase in the mean intraoperative BG concentration
.5.5 mM (100 mg dl21) was associated with a 34% increase
in experiencing a primary endpoint.67 Doenst and colleagues,65
in another cardiac surgical population, showed high peak BG
≥20mM(360mgdl21)wasan independentpredictorofmorbid-
ityandmortality indiabetic andnon-diabeticpatients. Interest-
ingly, patients with BG levels ,15 mM (270 mg dl21) were not
subject to worse outcomes.65 Ouattara and colleagues66
reported intraoperative hyperglycaemia, defined as more than
four consecutive BG values .11.11 mM (200 mg dl21) in a
study of 200 diabetic patients undergoing cardiac surgery, was
associated with poor cardiac and non-cardiac outcomes.
Intensive insulin therapy or conventional therapy
Historically, providers often allowed ‘permissive hypergly-
caemia’ under the (mis)assumption that the body needed
fuel to overcome surgical stress or critical illness.68 69 This ap-
proach was called into question after the landmark ICU inves-
tigation by Van den Berghe and colleagues in 2001.70 This
single-centre (Leuven, Belgium), randomized control trial of
1548mechanically ventilated, surgical ICU patients compared
intensive insulin therapy (IIT) with conventional treatment.
The BG target in the IIT group was 4.4–6.1 mM (80–110 mg
dl21), and 10–11.1 mM (180–200 mg dl21) in the control
group. The IIT group had reduced overall in-hospital mortality,
bloodstream infections, acute renal failure requiring dialysis or
haemofiltration, median number of red cell transfusions, and
critical illness polyneuropathy, and also shorter length of
mechanical ventilation and ICU stay. Mortality benefit was
Table 7 Instructions regarding preoperative insulin. Modified with permission from SAMBA58
Insulin regimen Day before surgery Day of surgery Comments
Insulin pump No change No change Use ‘sick day’ or sleep basal rates for outpatient
surgery, discontinue if planned admission
Long acting, peakless
insulins
No change 75–100% of morning dose Reduce nighttime dose if history of nocturnal or
morning hypoglycaemia
On the day of surgery, themorning dose of basal
insulin may be administered on arrival to facility
Intermediate-acting
insulins
No change in daytime dose,
75% of dose if taken in the
evening
50–75% of morning dose See comments for long-acting insulins
Fixed combination
Insulins
No change 50–75% of morning dose of
intermediate-acting component
Lispro-protamine only available in combination;
therefore, use NPH instead on day of surgery
See comments for long-acting insulins
Short- and rapid-acting
insulins
No change Hold the dose
Non-insulin injectables No change Hold the dose
Table 6 Pharmacology of insulin. Modified with permission from
SAMBA58
Drug class: generic
(trade name)
Onset Peak
effect
Duration
Short acting and rapid acting
Regular (Novolin R, Humulin R) 30–60
min
2–4 h 6–8 h
Lispro (Humalog) 5–15
min
30–90
min
4–6 h
Aspart (Novolog) 5–15
min
30–90
min
4–6 h
Glulisine (Apidra) 5–15
min
30–90
min
4–6 h
Intermediate acting
NPH (Novolin N, Humulin N-NF) 2–4 h 4–10 h 10–16 h
Zinc insulin (Lente) 2–4 h 4–10 h 12–20 h
Extended zinc insulin
(Ultralente)
6–10 h 10–16 h 18–24 h
Long acting (peakless)
Glargine (Lantus) 2–4 h None 20–24 h
Detemir (Levemir) 2–4 h None 20–24 h
Mixed insulins (NPH+regular)
70%NPH/30% regular (Novolin
70/30, Humulin 70/30)
30–90
min
Dual 10–16 h
50% NPH/50% regular
(Humulin 50/50)
30–90
min
Dual 10–16 h
Mixed insulins (intermediate-acting+rapid-acting analogues)
70% Aspart Protamine
suspension/30% Aspart
(Novolog mix 70/30)
5–15
min
Dual 10–16 h
75% Lispro Protamine
suspension/25% Lispro
(Humalog mix 75/25)
5–15
min
Dual 10–16 h
50% Lispro Protamine
suspension/50% Lispro
(Humalog mix 50/50)
5–15
min
Dual 10–12 h
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greatest inpatientswithan ICUstay≥5days.Patients in the IIT
arm, however, had significantly more hypoglycaemic events
(BG≤2.2mMor 40mgdl21) (5.1% vs0.8%)with noassociation
between hypoglycaemia and death.70 Various study limita-
tions were present, including the single-centre approach,
unblinded design, lack of targeted intraoperative glucose
control, and inclusion of primarily post-cardiac surgery
patients (63%) who received an atypical feeding protocol. An
unusually high mortality rate was also present in the control
group.71 Despite these limitations, this study is often referred
to as ‘that which launched a thousand protocols’.72
A secondLeuven studypublished in 2006 compared IITwith
conventional therapy in 1200medical ICU patients. It demon-
strated a decrease in renal injury, days of mechanical ventila-
tion, ICU LOS, and hospital LOS. It did not, however, show any
mortality benefit with IIT. Hypoglycaemic events were more
prevalent in the IIT group (18.7% vs 3.1%), likely related in
part to glucose measurement methodology. Importantly,
multivariate analysis demonstrated hypoglycaemia to be an
independent predictor of death.73 Pooled analysis of the two
Leuven studies suggested maintaining BG levels ,8.3 mM
(150mgdl21) to be themost important factor in reducingmor-
tality. In order to achieve renal and nervous systemprotection,
BG had to be kept ,6.1 mM (110 mg dl21). This tight level of
control did provide additional survival benefit. The pooled
data reaffirm the higher risk of hypoglycaemic events in the
IIT group (11.3% vs 1.8%).74
The risks of IIT were highlighted with the publication of
another landmark study, Normoglyacemia in Intensive Care
Evaluation and Survival Using Glucose Algorithm Regulation
(NICE-SUGAR). The goal of this study was to compare IIT (BG
goal 4.5–6mM, 81–108mgdl21)with conventional treatment
(BG goal 8–10 mM, 144–180 mg dl21). The NICE-SUGAR trial
was multicentre, international, and randomized. It included
6104 mixed medical and surgical (35%) ICU patients. The
authors were not able to demonstrate a difference in hospital
or ICU LOS, length of mechanical ventilation, or the need for
renal replacement. In contrast to the initial Leuven study,mor-
tality rates were higher in the IIT group (27.5% vs 24.9%). The
NICE-SUGAR trial reaffirmed a higher incidence of hypogly-
caemia in the IIT group. Along with other studies of its era,
NICE-SUGAR questioned the safety of IIT in critically ill
patients.75–77
Is there a role for intraoperative IIT? A study published in
2007 by Gandhi and colleagues64 attempted to answer this
question in a randomized, prospective fashion. Four hundred
adult patientsundergoingelective cardiacsurgerywere rando-
mized to either an IIT group (BG goal 4.4–5.5mM, 80–100mg
dl21) or a conventional treatment group (patients not given
insulin until BG .11.1 mM, 200 mg dl21). Both groups were
treated with insulin infusion after surgery to maintain normo-
glycaemia. The authors found more deaths (4 vs 0, P¼0.061)
and significantly more strokes (8 vs 1, P¼0.02) in the IIT
group. This finding led investigators to question the safety of
intraoperative IIT.64 A 2012 meta-analysis by Hua and collea-
gues,78 however, were able to show some benefit of intrao-
perative IIT. Data were pooled from five randomized control
trials; a total of 706 adult cardiac surgical patients were
assigned to either IIT or conventional therapy. There was no
statistically significant difference in 30 day or in-hospital mor-
tality (although the IIT group had seven deaths, and the con-
ventional treatment group had three). There was also no
difference in the number of hypoglycaemic events. Infection
rates, however, were significantly lower in the IIT group. The
authors caution that larger randomized trials are required
before the implementation of any strong, evidence-based
recommendations regarding intraoperative IIT.78
Treatment goals
Intraoperative IIT is currently not recommended because of
conflicting data and the risk of hypoglycaemia. The Society
for Ambulatory Anesthesia (SAMBA) and several authors
suggest following guidelines published by the American Asso-
ciation of Clinical Endocrinologists (AACE) and the ADA in their
Consensus Statement on Inpatient Glycemic Control.58 79 This
group suggests initiating treatment with an insulin infusion in
critically ill patients at a BG no greater than 10 mM (180 mg
dl21). Once treatment has begun, they suggest a target BG of
7.7–10 mM (140–180 mg dl21), recognizing that greater
benefit might be realized at the lower end of this range.
Finally, they admit that even lower targets might be beneficial
in some patient populations, but suggest never setting a BG
target below 6.1 mM (110 mg dl21).79 There are slight varia-
tions in suggested treatment thresholds and target glucose
levels when looking at recommendations from other promin-
ent medical societies; most, however, mirror those of the
ADA.20 80 81
Measurement and monitoring
Although the ADA recommends the use of insulin infusions for
critically ill patients, both the ADA and SAMBA suggest the use
of subcutaneous insulin for non-critical patients.29 58 This is
less labour intensive and more practical than i.v. administra-
tion in an outpatient setting.82 Absorption of subcutaneously
administered insulin can be variable, the time to onset can
be prolonged, and repeated doses can become ‘stacked’, in-
creasing the risk of hypoglycaemia.58 68 I.V. insulin has the
advantage of being quickly titratable with a rapid onset of
action. Insulin, irrespective of the route of administration, is a
dangerous drug; it is one of the five most common drugs
involved in clinically significant medical errors, and has the
highest rate of administration errors.10 83
The recommended frequency of intraoperative BGmonitor-
ing depends on many factors. In metabolically stable diabetic
patients undergoing short (,2 h), outpatient procedures, it is
only necessary to check BG on admission, before operation,
and on discharge. For longer outpatient procedures or for
patients receiving intraoperative subcutaneous insulin, it is ad-
visable to check BG levels every 1–2 h.58 Finally, for higher
acuity patients, patients having extensive surgical procedures,
or patients on insulin infusions, theADA recommends BGmon-
itoring as frequently as every 30 min.29
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Point-of-care (POC) testing is appropriate for BG measure-
ment in metabolically stable patients. This testing technique,
however, is considered less accurate than central laboratory
testing.84 The National Committee for Clinical Laboratory
Standards recommends differences between POC testing and
central laboratory testing not exceed +15% when glucose
concentrations are ,5.5 mM (100 mg dl21) and+20% when
glucose concentrations are .5.5 mM (100 mg dl21).85 Most
authors suggest a relatively high hypoglycaemia alert value
(e.g. 3.9 mM, 70 mg dl21) when using POC testing devices
and more frequent monitoring and routine central laboratory
confirmation of abnormal values.58 Many factors increase the
disparity between POC and central laboratory glucose mea-
surements. These include haemodynamic instability, shock,
anaemia, elevated bilirubin, uric acid, severe hyperlipidaemia,
and various medications including L-dopa, dopamine, manni-
tol, acetaminophen, and maltose.9 10 84 Most experts recom-
mend central laboratory testing or arterial blood gas analysis
formeasurementof glucose inhaemodynamicallyormetabol-
ically unstable patients.9 10 58 84
Postoperative care
The following reviews guidelines, recommendations, and
resultsof clinical trialsaimedatcompilingstatementsandsug-
gestions for postoperativeglucose control coveringa spectrum
of patients from those being discharged after ambulatory
surgery to those who require intensive care.
Post-anaesthesia care unit
The Diabetes UK Position Statements and Care Recommenda-
tions suggest maintaining BG in the range of 6–10 mM (108–
180 mg dl21) if safely achievable.3 Otherwise, a wider target
range of 4–12 mM (72–216 mg dl21) is acceptable.3 The cor-
rection of high BG can be achieved using subcutaneous
insulin or i.v. insulin.3 Depending on the present state and
comorbidities of an individual patient, capillary, venous, or
arterial BG levelsmust be assessed at least hourly, ormore fre-
quently if readings are outside the target range.3
Aggressivenauseaandvomitingprophylaxis andavoidance
of factors thatmight increasepostoperativenauseaandvomit-
ing (PONV), such as administration of opioids, should allow
early resumption of oral intake. Dexamethasone, a well-
established antiemetic, is frequently used for prevention of
PONV.86 Its use, even in small doses, has been shown to transi-
ently increaseBG levels. Dysglycaemicpatients receivingdexa-
methasone, or other steroid medications, should have
appropriatemonitoringofBG levels andcorrectionof hypergly-
caemia as needed.58
Ambulatory patients: SAMBA guidelines
Thanks to a comprehensive consensus statement issued by
SAMBA,wenowhave definitive guidelines to address theman-
agement of diabetic patients undergoing ambulatory surgery
procedures.58 Outpatient postoperative patients with abnor-
mal glucosehomeostasis shouldbeobserved inanambulatory
facility until the possibility of hypoglycaemia from periopera-
tively administered insulin is excluded and discharge criteria
are met (Table 8).87 Most ambulatory patients are able to
start early oral intake to counteract potential hypoglycaemia.
If this is not the case, theyshouldbemonitored foranappropri-
ate period of time after the last dose of insulin. The potential of
subcutaneous rapid-acting nutritional insulin to provokehypo-
glycaemia abates within 1.5 h (Table 6) in contrast to subcuta-
neous regular insulin, which subsides 3–4 h after the last dose
is administered.59 61 More frequent measurements than every
hour may be indicated for patients receiving intraoperative
insulin and in the case of lower BG levels.58
Intensive care unit
Glycaemic control in critically ill patients: waiting for
definitive answers
Critically ill patients frequently develop hyperglycaemia, even
without previous evidence of DM.1 Before 2001, SIH in critically
ill patientswasgenerallyacceptedasphysiologic.70 In theafter-
math of the Leuven trials, the concept of tight glucose control
was enthusiastically incorporated into guidelines including the
Surviving Sepsis Campaign 200488 and 2008,89 and those of
the ADA90 and the AACE.91 Subsequent trials only partially sup-
ported these findings or even failed to show a difference with
regard tomortality, revealinghigh incidencesof severehypogly-
caemic events as the most harmful complication.64 73 92–101
While hyperglycaemiamust be avoided, an optimal glucose
range for critically ill patients is a topic of ongoing discussion.
One trial reported the highest survival rates in ICU patients
with glucose levels between 6.2 and 8 mM (111–144mg dl21),
Table 8 Guidelines for glucose management in ambulatory patients58
Educate patients about signs and symptoms of potential hypoglycaemia and means to treat (15 g of oral dextrose to raise BG by 2.1 mM or
38 mg dl21 over 20 min). Best to use dextrose or sucrose tablets126
Follow routine antidiabetic (oral agents or insulin) guidelines for day of surgery
Check blood glucose on admission, before surgery, and before discharge at a minimum
Point-of-caremonitoring is sufficient for stable patients; higher threshold values for hypoglycaemia (e.g. ,3.9mM or 70mg dl21) andmore frequent
monitoring may be indicated to ensure patient safety
Provide educational material about restarting diet, oral antidiabetic agents, and insulin after discharge
Avoid overlap between pre-, intra-, and postoperative insulin
Resumption of preoperative antidiabetic regime should be based on perioperative course and is dependent on oral intake
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and the highest mortality rates with glucose levels .11.1 mM
(200mg dl21).102
Updated guidelines have reached a compromise and gen-
erally recommend a BG target of 7.7–10 mM (140–180 mg
dl21) for inpatients as long as these levels can be safely
achieved.79 80 103–105
Glucose targets and hyperglycaemia
Available studies on glucose targets in critically ill patients are
difficult to interpret because of substantial differences in study
populations and patient management at various centres.
Table 9 covers recommended glucose targets issued by diverse
societies including adaptations for subgroups at particular risk,
covering cardiac surgery, trauma, and neurological patients.
The rationale of the Society of Critical Care Medicine’s
practical guideline to start insulin infusion therapy at 8.3 mM
(150 mg dl21) is rooted in their meta-analysis indicating a
small,butsignificant, reduction in theodds ratio forhospitalmor-
tality without affecting ICU mortality.105 Higher trigger values
and BG excursions .10 mM (180 mg dl21) are associated with
immunosuppressive effects and the potential to exceed the
renal threshold for glucosuria.105 Other societies’ guidelines
propose a more relaxed BG trigger value of 10 mM (180 mg
dl21) to initiate insulin infusion,29 96 as there is no evidence that
targets between 7.7 and 10 mM (140–180 mg dl21) differ from
the lower target values of 6.1–7.7 mM (110–140mg dl21).103
Hypoglycaemia: adaptation of targets and treatment
Patients with moderate (BG 2.3–3.9 mM, 41–70 mg dl21) or
severe (BG ,2.2 mM, 40 mg dl21) hypoglycaemia have been
found to have a higher risk of death compared with those
without hypoglycaemia.6 Even one episode of hypoglycaemia
Table 9 Recommended glucose target ranges for intensive care patients and related subgroups
Society, guideline Patient group Trigger BG value
to start insulin
infusion, mM
(mg dl21)
Target range,
mM (mg dl21)
Rationale
Societyof Critical CareMedicine’s
clinical practice guideline105
General recommendation 8.3 (150) 5.6–8.3 (100–150)
Cardiac surgery ,8.3 (150) Decreased risk for deep
sternal wound infection and
death70 127–130
Critically ill trauma patients 8.3 (150) ,10 (180)
Traumatic brain injury131 132 8.3 (150) ,10 (180)
Neurological ICU patients
- Ischaemic stroke133–135
- Intraparenchymal
haemorrhage136
- Aneurysmal subarachnoid
haemorrhage137–139
8.3 (150) ,10 (180)
American Diabetes Association
guidelines29
General recommendation 10 (180) 7.8–10 (140–180)
Adaptation 6.1–7.8 (110–140) Adjust to lower target range in
documented low rate of severe
hypoglycaemia
American Association of Clinical
Endocrinologists111
General recommendation 7.8–10 (140–180)
Surgical patients Lower range Only in units showing low rates of
hypoglycaemia
Surviving Sepsis Campaign103 General recommendation 10 (180) ,10 (180) Based on NICE-SUGAR study
Clinical Practical Guideline from
the American College of
Physicians80
General recommendation 7.8–11.1 (140–200) If insulin infusion is applied. But
guideline does not recommend
intensive insulin therapy
Spanish Society of Intensive Care
Medicine and Coronary Units140
General recommendation ,8.3 (150)
French Society of Anaesthesia
and Intensive Care106
General recommendation 10 (180)
Surgical patients ,6.1 (110)
Cardiac patients ,6.1 (110)
Society of Thoracic Surgeons20 Cardiac surgery patients ,10 (180) except
,8.3 (150) for those
with devices in place
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is associated with higher mortality.94 BG values ,2.2 mM
(40 mg dl21) are an independent risk factor for mortality
after adjustment for severity of illness, age, mechanical venti-
lation, renal failure, sepsis, and DM.7
French guidelines define hypoglycaemia as BG ,3.3 mM
(60 mg dl21) and severe hypoglycaemia as BG ,2.2 mM
(40 mg dl21).106 Jacobi and colleagues105 propose an
adapted lower limit of 3.9 mM (70 mg dl21) for ICU trauma
patients, with the aim of lower infection rates and shorter ICU
stays. 107 108 Forpatientswithbrain injury, the lowestacceptable
BG level is 5.5 mM (100 mg dl21), as hypoglycaemia increases
the risk of focal neurological deficits, encephalopathy, seizures,
and permanent cognitive dysfunction in brain-injured
patients.105 Further clinical trials are necessary to define the
optimal BG range in this patient population, as case reports of
neuroglycopaenia and cerebral distress during insulin infusion,
independent of peripheral hypoglycaemia, leave the patho-
physiological importance of the rate of glucose change com-
pared with the hypoglycaemic incident unclear.109
In the case of BG levels ,3.9 mM (70 mg dl21), Jacobi and
colleagues105 suggest immediately stopping the insulin infu-
sion and administering titrated doses of 10–20 g of hypertonic
(50%) dextrose to avoid excessive replacement. BG measure-
ment should be repeatedafter 15minwith additional dextrose
asneeded tomaintain aBG level.3.9mM(70mgdl21).105 The
ADA recommends instituting a hypoglycaemia protocol and
suggests administering a 15–20 g bolus of i.v. dextrose, check-
ingBG level every 5–15min, and repeatingdextrose boluses as
indicated.29
Medication
Insulin infusion is themedication of choice for glucose control
in critically ill patients.2 29 110–112 Subcutaneous insulin can be
analternative treatment for selectedICUpatientswhoareclin-
ically stable and have low insulin requirements105 113 or when
preparing the stabilized patient for transition to theward. Such
anapproachmustbe individualizedandmightbe influencedby
hospital or unit policy (Table 10).
Glucose monitoring
Critically ill patients can also suffer from hypoglycaemia in the
absence of insulin treatment due to concomitant illness such
as liver disease, immune compromise, and renal failure.
Patients are also at risk for hypoglycaemia after interruption
of caloric intake, with the use of vasoactive infusions, or with
renal replacement therapy using bicarbonate-based replace-
ment fluid in sepsis.114 Arterial or venous whole blood sam-
pling is recommended for BG analysis whenever available
and particularly in patients suffering from shock, receiving
vasopressor therapy, those with severe peripheral oedema,
and those receiving prolonged insulin infusion.105
The Surviving Sepsis Campaign103 and Jacobi and collea-
gues105 propose a consensus recommendation based on
limited data where BG is monitored every 1–2 h during insulin
infusion. Protocols that propose checking glucose every 4 h
bear a .10% risk of unrecognized hypoglycaemia.70 94
Transition to ward or IMCU
Before discharge to the ward, the majority of stable ICU
patients should be transitioned to a protocol-driven basal/
bolus insulin regimen. This can be instituted before the
insulin infusion is discontinued to avoid marked swings in
BG.105 Transition should be put on hold until there are no
planned interruptions of nutrition, until peripheral oedema
has resolved, and until the patient is off vasopressors. When-
ever the BG target (,10mM, 180mgdl21) cannot be achieved
bysubcutaneous insulin, the regimenshouldbeadjustedor the
insulin infusion restarted.
Manyhospitals areunable to implement insulin infusionson
general floors or in the IMCU due to staffing policies. A basal/
bolus regimen derives a benefit in type 2 diabetics requiring
.0.5 units h21 of insulin and in non-diabetics requiring .1
units h21.115 Some institutions propose other cut-off values
or even suggest the exclusion of SIH patients from such transi-
tion.115–120 Calculation of basal and bolus insulin dosing
requirements should be based on previous i.v. insulin dosing
and concomitant carbohydrate intake. Most transitional
models propose a combination of basal insulin, nutritional
insulin, and correction insulin (Table 10).115–121 Supplemen-
tary correction insulin (in the form of a sliding scale) is titrated
according to long-acting insulin and basal–bolus orders. The
routine sole administration of sliding-scale insulin to control
BG on the ward, IMCU, or ICU is strongly discouraged because
of increased GV, incidence of hypo- and hyperglycaemia,122
and complications during hospitalization.29 111 123
Ward
There is no clear evidence for specific BG goals in non-critically ill
postoperativepatients.29 Patients treatedwith insulin shouldaim
at apre-meal BG,7.8mM (140mgdl21)with randomBGvalues
,10mM(180mgdl21),assumingthatthesetargetscanbesafely
achieved.29 123 More stringent targets can be suggested in
stable patients with previous tight glycaemic control.29 Less
stringent values might be appropriate in patients with severe
co-morbidities.29 Hence, for patients with terminal illness,
limited life expectancy, or a high risk of hypoglycaemia, a higher
BG target .11.1 mM (200mg dl21) might be reasonable.123 The
definition of hypoglycaemia does not differ based on patient
acuity or physical location. Hypoglycaemia is recognized as a
BG ,3.9 mM (70 mg dl21), which correlates with the threshold
for the release of counter-regulatory hormones, and severe
hypoglycaemia is defined as levels ,2.2mM (40mg dl21).29
Outside of the operating theatre and ICU, subcutaneous
insulin is recommended and generally accepted as the stand-
ardmethod of insulin administration.123 There is no study that
evaluates IIT in patients on the general ward. Scheduled sub-
cutaneous insulin should involve basal, nutritional, and correc-
tion components (with the latter two provided before meals)
and should be accompanied by meals with a consistent
amount of carbohydrate.123
Barriers to administering oral hypoglycaemic agents in
postoperative inpatients include variability in caloric intake,
ileus, and limited ability to titrate the drugs. Metformin, in
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Table 10 Concepts for transition from i.v. insulin therapy to subcutaneous insulin regimen. ICU, intensive care unit, BG, blood glucose, DM, diabetesmellitus, ADA, American Diabetes Association,
TDD, total daily dose
Donaldson and colleagues117 Furnary and Braithwaite116 O’Malley and colleagues115 Ramos and
colleagues118
Avanziniandcolleagues120 Magaji and
colleagues141
General
requirements
Extubated, off vasopressors, intra-aortic balloon pump out, stable renal function, no oedema
Indications for
transition
- Cardiac surgery
– Many patients require
perioperative insulin
infusion
– Many patients ready to
transition on postop. day
1, tolerance of oral intake
not essential
- Major surgery
– Mostpatients littleneed for
meal-time bolus in first
postop. days
– Non-diabetics with insulin
infusion .0.5 units h21
- Taking liquids/regularmeals
- Diabetic diet
- DM type 2 or
hospitalization-related
hyperglycaemia
- Receiving , 2 units h21
insulin infusion with BG
,7.2 mM (130 mg dl21)
- Basal insulin dose,48units
h21 during insulin infusion
- DM type 2 on insulin as
outpatient
- DM type 2with recentmean
insulin infusion rate of
.0.5 units h21
- Stress hyperglycaemia or
previously unrecognized
DM if insulin infusion rate
.1 units h21 or HbA1c
above normal
- Some institutions exclude
all stress hyperglycaemia
patients
- Patients on
medications for
diabetes
- HbA1c .6%
- Patients with
equivalent of . 60
mgof prednisone and
insulin infusion rate
.1 units h21
- Patients with stress
hyperglycaemia
regardless of insulin
infusion rate: no
transition to basal
subcutaneous insulin
- Mean dose of insulin
infusion in 24 h before
transition ,1.6 units
h21
- BG coefficient of variation
in 24 h before transition
,11.9%
Patients eating
reliably
Calculation of
daily insulin
dose
Last stable insulin infusion
rate×24¼24 h insulin dose
Average insulin infusion rate
in 6–8 h interval while being
NPO and receiving no i.v.
dextrose:
6 h total dose×4 or 8 h total
dose×3
TDD of insulin for 24 h full
nutrition:
(1) Mean insulin infusion rate
per hour from last
6 to 8 h
(2) Hourly rate×24, then
multiply by 0.7 or
0.8¼safety-adjusted
insulin dose
TDD¼averaging hourly
drip rate over prior 6 h
multiplied
- By 20 if taking full
nutrition (.50% of
calories)
- By 40 if taking minimal
nutrition (NPO,,50%
of calories)
Estimate of combined basal
and nutritional
subcutaneous insulin
requirements
- Average insulin infusion
rate in last 12 h¼mean
hourly ratemultiplied
by 24¼daily insulin
requirement
- Patient’s hourly
insulin infusion
rate while
NPO×24¼24 h
basal insulin dose
during stress
Basal insulin 80% of 24 h insulin dose¼first
dose of glargine
Initial glargine dose¼80% of
the 24 h basal insulin
requirement
Glargine or detemir
- 40–50% of TDD
50%of TDD¼first doseof
glargine
Halve daily insulin
requirement¼basal insulin
dose
Adjusted basal dose
accounting for stress
reduction¼2/3×24 h
basal insulin dose
during stress¼units of
glargine
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Bolus
(mealtime)
insulin
Post-prandial BG .7.8 mmol
litre21 (140 mg dl21): add 25%
of daily dose of glargine as
rapid-acting insulin with each
meal
Initiation with first dietary
trays, even if insulin infusion
still running
Remainder of the
TDD¼scheduled nutritional
insulin. Estimation of first
dose:
- 50% of the TDD as
nutritional coverage,
divided by 3 to determine
mealtime bolus (hold if
,50% of meal is eaten)
- More conservative: 10–20%
of basal dose for every
meal
50% of TDD divided into
- regular insulin every 6 h
for patients on tube
feeds OR
- lispro (Humalog) before
meals if tolerating
oral diet
Patients on minimal
nutrition: hold 50%
nutritional dose until full
nutrition tolerated
Halve daily insulin
requirement and split into:
- 20% at breakfast
- 40% at lunch
- 40% at dinner
- Provide as soon
patients start
eating
- Depend on patients’
caloric intake
- Start with 10% of
adjusted basal
dose, given at each
meal
Conversion
protocol
Overlap first glargine dose with
insulin infusion by several hours
Stop insulin infusion 2 h after
first glargine dose
- Basal insulin at least 2 h
before insulin infusion
stops
- Shorter lead time (30 min)
possible if rapid-acting
insulin is given with basal
insulin
Basal insulin
administration 2 h
before insulin infusion
stopped
Give first basal insulin dose
2 h before first meal and
discontinuation of insulin
infusion and i.v. dextrose.
- Continue insulin
infusion at least 4 h
after first glargine
dose
- Stop insulin infusion
sooner when
glargine and
rapid-acting
meal-time bolus
are given
Monitoring BG
measurements
- Adapt glargine every 24 h
- Patients without previous DM
and normal HbA1c: taper
glargine by 20% of first dose
per day and discharge
without prescription
- Patients with previous DM:
maintain on glargine and
mealtime insulin until
discharge (transition
glargine to previous
outpatient therapy modified
as required by HbA1c)
BG measurement at:
Pre-prandially
2 h post-prandially
bedtime
3.00 am
Revise total 24 h dose daily
Revise distribution of basal
and prandial insulin daily
to approach 50% basal
and 50% prandial
Use carbohydrate counting
to cover nutritional intake
- Increase mealtime
boluses daily
according tocaloric
intake
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particular, should likely be restarted no earlier than 48 h after
surgery when no renal insufficiency or nausea and vomiting
are present.112 124 Patients whose glycaemic status was well
controlled before hospital admission, however, can usually
transition to oral agents 1 or 2 days before discharge.29 111
Patients on home insulin regimes should ideally resume their
preadmission schedule at least 1 day before discharge.123
Conclusion
Perioperative dysglycaemia in the adult surgical population
is ubiquitous, and unfortunately often undiagnosed. The pre-
ponderance of evidence indicates that abnormal glucose
homeostasis has an adverse effect on patient outcomes.
Anaesthesiologists, as leaders of the ‘surgical home’ model,
are perfectly poised to aid in the identification of these
patients, initiate treatment, and facilitate referrals for post-
operative care. Given theheterogeneous nature of this popula-
tion, it is unlikely that one standard of perioperative glycaemic
control is appropriate forall patients. Certainly, early identifica-
tion coupledwith timely intervention contributes to significant
risk reduction. Although not clearly delineated, the desired
level of intraoperative and postoperative glucose control
rests somewhere between strict control and overt hypergly-
caemia; the goal being adequate control and avoidance of
hypoglycaemia. Future investigationswill help identify specific
perioperative glucose targets, especially in specialized surgical
populations (i.e. cardiac, neurosurgical), while advances in
monitoring andmedicationswillmake it easier to achieve spe-
cific glucose targets in individual patients. Closed-loop, con-
tinuous monitoring, and management systems with smart
alarms and clinical interfaces to enhance glycaemic control
are likely to be forthcoming, but are currently not clinically
available.125
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